MYOMO, INC.

MYOMO's capital structure is characterized by a high liquidity position, with cash and equivalents amounting to $11,971,426 as of Q1 2026, which is significantly higher than its short-term debt of $2,733,243. The company's current ratio of 2.73 indicates a strong ability to meet short-term obligations. However, the company's price-to-book ratio of 4.06 suggests that the market is valuing the company's equity at a premium relative to its book value, which may reflect expectations of future growth or intangible assets not captured in the balance sheet. Profitability metrics for MYOMO are negative, with a net loss of $3,009,399 and an operating loss of $3,157,052 in Q1 2026. The company's return on equity is -33.43%, and its return on assets is -8.19%, both of which are significantly below the industry median for medical device companies. These figures indicate that the company is not generating returns for its shareholders and is underperforming in terms of asset utilization. MYOMO's revenue is concentrated in a single segment, as disclosed in its financial statements, with no detailed breakdown of geographic exposure. The company's primary source of revenue is from contracts with customers, but the lack of segment-specific data makes it difficult to assess the diversification of its revenue streams. The company's reliance on a single product line and customer base could expose it to significant revenue volatility if market conditions change. The company's growth trajectory is uncertain, with a net loss in Q1 2026 compared to a net loss in Q1 2025. The company's operating cash flow is negative, and its free cash flow is also negative, indicating that the company is not generating sufficient cash from operations to fund its activities. The company's capital expenditures of $327,807 in Q1 2026 suggest ongoing investment in its operations, but the lack of positive cash flow from operations raises concerns about the sustainability of these investments. Risk factors for MYOMO include a high dilution potential, as evidenced by the significant difference between the basic and diluted share counts. The company's risk assessment indicates a high dilution risk, with the potential for further dilution if warrants are exercised or if Avenue Capital Management II, L.P. elects to convert principal payments into common stock. The company's liquidity risk is low, but its credit risk is not explicitly stated in the provided data. Recent events, as disclosed in the company's filings, include a net loss of $3,009,400 in Q1 2026 and an accumulated deficit of $121,697,800 as of March 31, 2026. The company has access to capital resources through possible public or private equity offerings, but it also faces risks related to the impairment of capitalized internal-use software and the potential for delayed cash flow breakeven due to investments in R&D and manufacturing capacity. The company also faces regulatory risks related to Medicare coverage requirements for its MyoPro device.